Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Emergent BioSolutions's Total Liabilities for the quarter that ended in Jun. 2026 was €673.0 Mil. Emergent BioSolutions's Total Assets for the quarter that ended in Jun. 2026 was €969.4 Mil.
Therefore, Emergent BioSolutions's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.69.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Emergent BioSolutions Liabilities-to-Assets Related Terms
Emergent BioSolutions Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ER4 vs ELTP, ANIK, AKBA: Liabilities-to-Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Liabilities-to-Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Emergent BioSolutions's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (FRA:ER4) has a Liabilities-to-Assets of 0.69 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Liabilities-to-Assets too high?
Emergent BioSolutions' current Liabilities-to-Assets is 0.69. Overall, Emergent BioSolutions has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Liabilities-to-Assets compare to ELTP and ANIK?
Emergent BioSolutions' Liabilities-to-Assets of 0.69 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Liabilities-to-Assets is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.62, compared to a current price of €5.29 — trading 14.5% above its estimated fair value. The current Liabilities-to-Assets is 0.69. Emergent BioSolutions' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Liabilities-to-Assets is 0.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €5.29 is trading 14.5% above its estimated GF Value™ of €4.62.
GuruFocus considers Emergent BioSolutions to be Modestly Overvalued.
Key valuation signals for FRA:ER4:
Liabilities-to-Assets: 0.69
GF Value™: €4.62 vs. price of €5.29 (14.5% above fair value)
No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
63GF Score
Get the complete analysis for FRA:ER4
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ER4 has been successfully added to your 
